BIOMAT Database Logo BIOMAT Database Logo

N-terminal pro-brain natriuretic peptide in systemic sclerosis: new insights. 2011

Hebatallah Ahmad Elshamy, and Soha Eldessouki Ibrahim, and Hanan Mohamed Farouk, and Afaf A Moustafa, and Iman Mohamed Aly, and Wesam M Osman
Department of Rheumatology & Rehabilitation, Ain Shams University, Cairo, Egypt.

OBJECTIVE To identify the relation between serum levels of N-terminal pro-brain natriuretic peptide (NT-pro BNP) and severity of systemic sclerosis (SSc). METHODS 25 SSc patients and 25 age- and sex-matched healthy controls were included. Assay of serum NT-pro BNP was done for all patients and controls. Patients were subjected to modified Rodnan skin score (mRss), echocardiography, pulmonary function tests and skin biopsies for histopathological skin thickness score assessment. There was a significant increase in the mean values of serum levels of NT- pro BNP in SSc patients compared to controls (t=11, p<0.001). RESULTS There was a significant positive correlation between serum levels of NT-pro BNP in SSc patients and mRss, systolic pulmonary artery pressure (sPAP) and histopathological skin thickness score (r=0.93, r=0.92, r=0.92, p<0.001 respectively). There was a significant increase in the mean value of serum levels of NT-pro BNP and sPAP in SSc patients with restrictive pulmonary affection compared to those with normal respiratory function tests (p<0.001). CONCLUSIONS NT-pro BNP may be a useful biological marker for assessing the severity of SSc as it has a role in detecting the extent of skin fibrosis, the severity of PAH and the degree of restricted pulmonary involvement in SSc patients.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D012129 Respiratory Function Tests Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc. Lung Function Tests,Pulmonary Function Tests,Function Test, Pulmonary,Function Tests, Pulmonary,Pulmonary Function Test,Test, Pulmonary Function,Tests, Pulmonary Function,Function Test, Lung,Function Test, Respiratory,Function Tests, Lung,Function Tests, Respiratory,Lung Function Test,Respiratory Function Test,Test, Lung Function,Test, Respiratory Function,Tests, Lung Function,Tests, Respiratory Function
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012595 Scleroderma, Systemic A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA. Sclerosis, Systemic,Systemic Scleroderma,Systemic Sclerosis

Related Publications

Hebatallah Ahmad Elshamy, and Soha Eldessouki Ibrahim, and Hanan Mohamed Farouk, and Afaf A Moustafa, and Iman Mohamed Aly, and Wesam M Osman
N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment?
December 2009, Annals of the rheumatic diseases,
Hebatallah Ahmad Elshamy, and Soha Eldessouki Ibrahim, and Hanan Mohamed Farouk, and Afaf A Moustafa, and Iman Mohamed Aly, and Wesam M Osman
N-terminal pro brain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis.
January 2009, Clinical and experimental rheumatology,
Hebatallah Ahmad Elshamy, and Soha Eldessouki Ibrahim, and Hanan Mohamed Farouk, and Afaf A Moustafa, and Iman Mohamed Aly, and Wesam M Osman
Serum N-terminal pro-brain natriuretic peptide, a marker of skin thickness in systemic sclerosis?
February 2009, Clinical rheumatology,
Hebatallah Ahmad Elshamy, and Soha Eldessouki Ibrahim, and Hanan Mohamed Farouk, and Afaf A Moustafa, and Iman Mohamed Aly, and Wesam M Osman
N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis.
November 2016, International journal of cardiology,
Hebatallah Ahmad Elshamy, and Soha Eldessouki Ibrahim, and Hanan Mohamed Farouk, and Afaf A Moustafa, and Iman Mohamed Aly, and Wesam M Osman
The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients.
April 2008, Clinical rheumatology,
Hebatallah Ahmad Elshamy, and Soha Eldessouki Ibrahim, and Hanan Mohamed Farouk, and Afaf A Moustafa, and Iman Mohamed Aly, and Wesam M Osman
N-terminal pro-brain natriuretic peptide in systemic sclerosis related pulmonary arterial hypertension under bosentan treatment.
January 2009, Rheumatology international,
Hebatallah Ahmad Elshamy, and Soha Eldessouki Ibrahim, and Hanan Mohamed Farouk, and Afaf A Moustafa, and Iman Mohamed Aly, and Wesam M Osman
N-Terminal Pro-Brain Natriuretic Peptide Trial Design.
August 2017, American journal of respiratory and critical care medicine,
Hebatallah Ahmad Elshamy, and Soha Eldessouki Ibrahim, and Hanan Mohamed Farouk, and Afaf A Moustafa, and Iman Mohamed Aly, and Wesam M Osman
Pediatric brain natriuretic peptide and N-terminal pro-brain natriuretic peptide reference intervals.
April 2006, Clinica chimica acta; international journal of clinical chemistry,
Hebatallah Ahmad Elshamy, and Soha Eldessouki Ibrahim, and Hanan Mohamed Farouk, and Afaf A Moustafa, and Iman Mohamed Aly, and Wesam M Osman
Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction.
August 2001, Clinica chimica acta; international journal of clinical chemistry,
Hebatallah Ahmad Elshamy, and Soha Eldessouki Ibrahim, and Hanan Mohamed Farouk, and Afaf A Moustafa, and Iman Mohamed Aly, and Wesam M Osman
Role of N-terminal pro-brain natriuretic peptide in detecting clinically significant cardiac involvement in systemic sclerosis patients.
January 2012, Clinical and experimental rheumatology,
Copied contents to your clipboard!